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Abstract
Background: The increased risk of new-onset diabetes with statin use, including high-potency statins, is well
known. However, the effects of high-potency statins on HbA1c are unclear. A retrospective cohort study was
conducted to examine the effect of high-potency statins on HbA1c in patients with or without diabetes. The study
enrolled new statin users identified via the electronic healthcare database of the general hospital in Japan.
Methods: Following identification of all individuals (n = 4,672) who had been prescribed a lipid lowering drug at
least once between January 1, 2010 and July 31, 2014, new statin users were selected (n = 1,136). Patients were
excluded if they had been prescribed treatment with a statin within the preceding 6-month period. HbA1c levels
before and during high-potency statin treatment were compared using the dependent t-test. In addition, the
hazard ratio for the incidence of diabetes with high-potency statin treatment was estimated, using low-potency
statins as a reference.
Results: In patients with diabetes (n = 153), mean HbA1c (%) levels significantly increased by 0.4 % after high-
potency statin use (7.57 ± 1.58; p = 0.0002) compared to baseline (7.18 ± 1.37). Similarly, HbA1c (%) levels
significantly increased from 5.78 ± 0.38 to 5.92 ± 0.45 (p < 0.0001) after high-potency statin use in patients without
diabetes (n = 165). Furthermore, a trend toward an increase in HbA1c was found for all of the high-potency statins
irrespective of a history of diabetes.
Conclusions: The use of high-potency statins may increase HbA1c levels in patients with or without diabetes.
Keywords: High-potency statin, Hemoglobin A1c, New-user design
Background
Statins have been widely used for the prevention of car-
diovascular disease [1, 2]. In Japan, the estimated num-
ber of patients with hyperlipidemia was approximately
1.9 million in 2011 [3]. It is essential to manage hyper-
lipidemia with statins to prevent the incidence of cardio-
vascular disease. However, statins are associated with
major adverse effects including liver enzyme abnormal-
ities and muscle toxicity, including rhabdomyolysis [4].
A meta-analysis by Sattar et al. [5] found that statin use
was also associated with an increased risk of new-onset
diabetes (overall odds ratio [OR] = 1.09; 95 % confidence
interval [CI]: 1.02–1.17), and that the OR varied according
to the potency of the statin. For high-potency statins (ator-
vastatin and rosuvastatin), the OR was 1.14–1.18, and for
low-potency statins (simvastatin, pravastatin, and lova-
statin), the OR was 0.98–1.11. A population-based retro-
spective cohort study in Canada that used administrative
healthcare databases indicated that the risk of diabetes
with high-potency statins was higher than with low-
potency statins (hazard ratio [HR] = 1.22; 95%CI: 1.15–
1.29) [6]. Therefore, the risk of new-onset diabetes may be
different between low- and high-potency statins.
A recent meta-analysis found that statin treatment was
associated with a modest increase in hemoglobin A1c
(HbA1c, or glycated hemoglobin) in patients with dia-
betes [7]. Atorvastatin, a high-potency statin, had a par-
ticularly marked effect on HbA1c. A randomized
controlled study of patients with type 2 diabetes con-
ducted in Taiwan found that HbA1c was significantly
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increased after 3 months in patients receiving atorva-
statin (6.5 % versus 6.6 %), while levels remained un-
changed in those receiving pitavastatin (6.5 % versus
6.5 %), which has a similar potency [8]. On the other
hand, in a randomized study of non-diabetic patients,
neither of the high-potency statins investigated (atorva-
statin and rosuvastatin) had a significant effect on
HbA1c [9].
The effects on HbA1c might be different between dif-
ferent high-potency statins, and between patients with
and without diabetes. Therefore, a retrospective cohort
study was conducted to examine the effects of high-
potency statins on HbA1c levels in patients with or
without diabetes.
Methods
Study design and population
The data for this retrospective cohort study were ob-
tained from the Hitachinaka General Hospital in Japan,
which has approximately 300 beds. The data collected
for each patient included study ID number; age and sex;
ICD-10 (10th revision of the international classification
of diseases) diagnosis codes; laboratory test results, in-
cluding HbA1c (%); ordering laboratory tests for lipids;
and the generic name, date, and number of days of sup-
ply of prescribed/dispensed drugs. A study ID number
was created for each patient by the researcher within the
study hospital.
Figure 1 shows the patient selection flow. All patients
with hyperlipidemia who had started treatment with a
statin (after 6 months of non-use) in the study hospital
were identified. First, patients who had been prescribed
a lipid lowering drug at least once between January 1,
2010 and July 31, 2014 were identified by using the hos-
pital information system, which included electronic
prescription and medical records (diagnoses and the
items or results of laboratory tests). Second, to identify
the new statin users, patients were excluded if they had
been prescribed the same or another statin in the pre-
ceding 6-month period. Pravastatin, simvastatin, and flu-
vastatin were defined as low-potency statins, and
atorvastatin, pitavastatin, and rosuvastatin were defined
as high-potency statins [6, 10]. Although data on the po-
tency of pitavastatin is lacking, we considered pitavasta-
tin as a high-potency statin because the reported effect
of pitavastatin is similar to atorvastatin [11]. In addition,
patients with diabetes receiving low-potency statins were
excluded, as were patients receiving fibrates or ezeti-
mibe. Finally, patients receiving high-potency statins
were included in the study cohort for comparison of la-
boratory test results before and during statin treatment.
Effects of high-potency statins on HbA1c
As this was an observational study using retrospective
data, the doctors were not required to test for glycemic
control prior to treatment with statins or at specific time
points during treatment. The baseline HbA1c level was
defined as the most recent measurement taken prior to
initiation of low- or high-potency statin treatment. For
each patient, the baseline value was compared with the
HbA1c measurement taken after initiation of statin
treatment; the time point for which varied in patients. In
addition, the change in HbA1c was compared between
patients with and without diabetes. To analyze HbA1c,
we used the criteria set by the National Glycohemoglo-
bin Standardization Program (NGSP). We also included
the Japan Diabetes Society (JDS) criteria, as the NGSP
HbA1c criteria are obtained by adding 0.4 % to the JDS
HbA1c criteria [12].
Fig. 1 Patient selection flow
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For each patient, the start date was when statin treat-
ment began. The study endpoint was defined as i) a new
occurrence of diabetes (defined by an ICD-10 diagnosis
code for diabetes or prescription of antidiabetic drugs in-
cluding insulin), ii) discontinuation of statin treatment, iii)
switching to another statin, or iv) July 31, 2014, whichever
came first. Continuous statin use was defined using a
grace period of up to 15 days between prescription dates.
Ethics
The study protocol was approved by the ethics review
committee of the Hitachinaka General Hospital (Ibaraki,
Japan), and the Nihon University School of Pharmacy (No.
14–013). The waiver of informed consent from individual
patients was approved by the ethics committee. Anon-
ymized data with serial study ID numbers created by the
study hospital were used throughout the study.
Statistical analysis
The distribution of baseline characteristics during the
preceding 6 months for new users of high-potency
statins were described according to the history of dia-
betes. The definition of diabetes was based on the record
of the ICD-10 code for diabetes or the prescription of
antidiabetic drugs including insulin. A proportion in-
cluding some covariates that may affect the incidence of
diabetes, are shown in Table 1. The covariates included
age, sex, mean follow-up (days), laboratory tests for
HbA1c and lipids, use of concomitant drugs (systemic
corticosteroids; thiazide diuretics; adrenergic beta-
antagonists; antihypertensives including calcium-channel
blockers [CCBs], angiotensin converting enzyme inhibi-
tors [ACEIs] or angiotensin-receptor blockers [ARBs];
and antipsychotics), comorbidities (myocardial infarc-
tion, chronic heart failure, renal disease, liver disease,
pulmonary disease, and hypertension), and Charlson Co-
morbidity Index [13]. To classify comorbidities [13], we
used the following ICD-10 codes; diabetes (E10, E11,
E13 and E14), hypertension (I10 and I15), myocardial in-
farction (I21, I22 and I23), chronic heart failure (I11),
renal disease (I12, I13, N00 to N05, N11, N14, N17 to
N19 and Q61), liver disease (B15, B16, B18, I85 and K70
Table 1 Baseline characteristics for patients receiving high-potency statins
Patients with diabetes (n = 276) Patients without diabetes (n = 659)
Atorvastatin Pitavastatin Rosuvastatin P-value Atorvastatin Pitavastatin Rosuvastatin p-value
Number of patients 87 70 119 - 221 151 287 -
Mean follow-up days 262 313 303 0.60 243 314 352 0.01
Male, % 75.9 65.7 62.2 0.11 52.0 53.0 57.5 0.43
Age, years, mean ± SD 66.2 ± 11 65.8 ± 12 67.5 ± 12 0.56 68.1 ± 11 67.4 ± 11 66.0 ± 12 0.12
Disease, %
Diabetes 96.6 97.1 97.4 0.93 0 0 0 -
Hypertension 72.4 57.1 70.6 0.09 48.4 58.3 55.0 0.30
Myocardial infarction 12.6 11.4 18.5 0.33 17.6 17.2 19.5 0.80
Chronic heart failure 18.4 14.3 21.0 0.52 16.7 17.2 22.0 0.27
Renal disease 12.6 5.7 16.0 0.12 11.7 17.9 10.8 0.09
Liver disease 8.0 8.6 11.8 0.63 9.5 7.3 13.6 0.10
Pulmonary disease 13.8 14.3 12.6 0.94 14.9 13.2 19.1 0.22
CCI, mean 1.3 1.4 1.3 0.50 1.2 1.3 1.3 0.88
Concomitant medications, %
Antidiabetics (insulin) 86.2 (10.3) 81.4 (10.0) 80.7 (8.6) 0.56 0 0 0 -
ACEIs or ARBs 47.1 47.1 47.1 0.99 35.3 40.4 33.8 0.39
Beta-blockers 25.3 10.0 31.9 0.003 21.2 26.5 22.0 0.45
Thiazides 4.6 8.6 6.8 0.60 4.5 1.3 5.9 0.08
CCBs 39.1 28.6 41.1 0.21 43.0 34.4 31.7 0.03
Antipsychotics 0 0 4.2 0.03 3.2 3.3 1.7 0.49
Laboratory tests
HbA1c, %, mean (n) 6.9 (74) 7.3 (58) 7.0 (97) 0.14 5.7 (115) 5.8 (72) 5.8 (153) 0.67
Ordering Llipids, % 92.0 94.3 93.3 0.85 86.9 83.4 86.8 0.58
Abbreviations: ACEIs angiotensin converting enzyme inhibitors, ARBs angiotensin-receptor blockers, CCBs calcium-channel blockers, CCI Charlson Comorbidity Index,
HbA1c hemoglobin A1c, SD standard deviation
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to K76), and pulmonary disease (J40 to J47, J60 to J67,
J70, J84, J96 and J98). The chi-square test was used to
evaluate the differences between the high-potency sta-
tins. HbA1c levels before and during statin treatment
were compared using the dependent t-test.
For the sensitivity analysis, we restricted the popula-
tion to patients without diabetes, and calculated the haz-
ard ratio (HR) for new-onset diabetes with low-potency
statins and high-potency statins using the Cox propor-
tional hazards regression model. Unadjusted and
multivariate-adjusted HRs were estimated with 95 % CIs
for new-onset diabetes with high-potency statin treat-
ment. A p-value <0.05 was considered statistically sig-
nificant. All analyses were conducted using SAS, version
9.4 (SAS Institute, Cary, NC, USA).
Results
Baseline characteristics
In total, 1,136 new statin users were identified. Of these,
935 (82.3 %) were receiving a high-potency statin. Of the
patients receiving high-potency statins, 276 (29.5 %) had
a medical history of diabetes. Table 1 shows the baseline
characteristics for the patients receiving high-potency
statins by history of diabetes. Mean follow-up days of
patients without diabetes were different between statin
groups. The mean age was similar between patients with
and without diabetes, while a larger proportion of pa-
tients with diabetes were male compared to patients
without diabetes. The use of concomitant beta-blockers
or antipsychotic drugs in patients with diabetes, and use of
CCBs in patients without diabetes were significantly differ-
ent between the high-potency statins. However, no other
significant between-group differences were apparent.
Changes in HbA1c in new users of high-potency statins
Table 2 shows the change in HbA1c with low-potency or
high-potency statin treatment. With low-potency statin use
as the control, 34 % (n = 22/64) of the patients with dia-
betes had HbA1c measurements for both before and dur-
ing statin treatment while only 7 % (n = 10/137) of the
patients without diabetes had both measurements available.
With high-potency statin use, 55 % (n = 153/276) of the pa-
tients with diabetes had HbA1c measurements for both be-
fore and during statin treatment; 25 % (n = 165/659) of the
patients without diabetes had both measurements available.
Compared with the baseline value, the use of high-potency
statins significantly increased HbA1c levels in patients both
with and without diabetes. The effect on HbA1c levels was
significantly higher in patients with diabetes compared to
those without (p = 0.02). A similar trend was observed for
each of the high-potency statin drugs. Although the use of
low-potency statins tended to increase HbA1c levels in pa-
tients both with and without diabetes, the difference was
not significant (p = 0.89).
New-onset diabetes risk with high-potency statins
Table 3 shows the number of cases of new-onset dia-
betes and the unadjusted/adjusted HRs for diabetes
Table 2 Change in HbA1c in new users of high-potency statins or low-potency statins as the control group
High-potency statins Atorvastatin Pitavastatin Rosuvastatin Low-potency statins
With diabetes
Number of patients 153 47 42 64 22
Mean period (days)a 209 166 189 254 231
HbA1c (%), mean ± SD
Before 7.18 ± 1.37 7.03 ± 1.31 7.57 ± 1.64 7.03 ± 1.17 6.95 ± 1.92
After 7.57 ± 1.58 7.25 ± 1.21 8.11 ± 1.79 7.45 ± 1.61 7.25 ± 1.29
Difference 0.39 ± 1.27 0.21 ± 0.75 0.54 ± 1.61 0.42 ± 1.32 0.30 ± 0.94
p-value 0.0002 0.05 0.04 0.01 0.15
Without diabetes
Number of patients 165 49 31 85 10
Mean period (days)a 239 212 310 229 236
HbA1c (%), mean ± SD
Before 5.78 ± 0.38 5.76 ± 0.42 5.69 ± 0.24 5.81 ± 0.41 5.80 ± 0.47
After 5.92 ± 0.45 5.95 ± 0.45 5.90 ± 0.48 5.92 ± 0.45 6.07 ± 0.58
Difference 0.15 ± 0.31 0.19 ± 0.31 0.21 ± 0.46 0.10 ± 0.22 0.27 ± 0.18
p-value <0.0001 0.0001 0.02 <0.0001 0.001
p-valueb 0.02 − − − 0.89
Abbreviations: SD standard deviation
aDifference between statin start date and HbA1c measurement date
bComparison of differences in HbA1c between diabetes and non-diabetes
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associated with high-potency statins, using low-potency
statins as a reference. The number of new cases of dia-
betes was small. Of the 11 cases of diabetes, 8 were iden-
tified by concomitant antidiabetic drug use in addition
to an ICD-10 diagnostic code. The unadjusted/adjusted
HRs for diabetes with high-potency statin treatment
were 1.3 and 1.4, respectively; however, the 95 % CIs
were wide.
Discussion
In this retrospective cohort study, we examined whether
the use of high-potency statins may have an effect on
HbA1c levels. The use of high-potency statins increased
HbA1c levels irrespective of a history of diabetes. How-
ever, the degree of the effect of high-potency statins on
HbA1c was significantly higher in patients with diabetes
compared to those without diabetes. For the risk of new-
onset diabetes, the adjusted HR for high-potency statins
was 1.4, when low-potency statins were used as a refer-
ence; however, the 95 % CI was wide.
The risk of diabetes may differ between the low and
high-potency statins. A meta-analysis [5] suggested that
the risk of new-onset diabetes with high-potency statins
(atorvastatin or rosuvastatin) may be modestly higher
than with low-potency statins (pravastatin, simvastatin,
or lovastatin). Furthermore, in an observational study
using administrative healthcare databases, the risk of
new-onset diabetes was found to be higher with high-
potency statins than with low-potency statins [6]. Similar
to those of previous studies [5, 6], our findings suggest
that the risk of diabetes with high-potency statin treat-
ment may be higher, although the 95 % CI was wide and
the number of the cases of new-onset diabetes was
small.
In our study, claims data and laboratory test results,
including those for HbA1c, were available. A previous
observational study [6] using claims database did not in-
clude laboratory test results. However, to examine the
risk of diabetes with high-potency statin use, it is essen-
tial to compare HbA1c values before and after statin
use.
We observed an increase in HbA1c with high-potency
statins irrespective of a history of diabetes. Although the
effect of pitavastatin, a high-potency statin, on glucose
metabolism in patients with diabetes is under debate,
the other two high-potency statins investigated here
(atorvastatin and rosuvastatin) may also have an effect
on HbA1c. The results of a meta-analysis on statins and
glycemic control [7] and the findings of several other
studies in patients with diabetes [14–16] suggest that
statin treatment is associated with a modest increase in
HbA1c. Our findings for patients with diabetes are con-
sistent with these studies, with the exception of pitavas-
tatin. On the other hand, the effect of high-potency
statins on HbA1c in patients without diabetes may still
be unclear, despite increased HbA1c levels observed in
our study. A randomized trial of two high-potency sta-
tins (atorvastatin and rosuvastatin) in patients without
diabetes reported that HbA1c levels were similar to
baseline after 3 months of treatment [9]. In contrast, in
another randomized trial of rosuvastatin, HbA1c levels
increased from 5.7 to 5.9 % in patients without diabetes
[17]. However, these randomized trials were not de-
signed to evaluate the incidence of diabetes and the pa-
tient selection criteria were different than those in our
study.
Our study has some limitations. First, the proportion
of patients with laboratory test results, such as HbA1c,
for both baseline and during statin treatment was low as
this observational study was conducted in a real-world
setting. The most common reason to order a laboratory
test is to follow up on an abnormal finding or to moni-
tor therapy [18]. As our study patients had hyperlipid-
emia, the proportion of laboratory tests performed to
assess lipids at baseline was high (83 %). Around 80 % of
the patients with diabetes had HbA1c measurements at
baseline, but the proportion of patients without diabetes
with HbA1c baseline measurements was approximately
50 %. In clinical practice, physicians might not monitor
the effect of high-potency statins on glycemic control.
Second, the diagnosis code for diabetes was not vali-
dated in our database, which may explain the uncer-
tainty of the HR for diabetes with high-potency statin
treatment. Although the number of new diabetes cases
was small, 73 % of cases were recognized through con-
comitant antidiabetic drug use. Third, our study popula-
tion, which was composed of new high-potency statin
users, may lack generalizability as we used the data from
a single district general hospital. However, all Japanese
citizens are provided with care and treatment at any
time and at the place of their choice, regardless of the
type of facility, by universal health insurance coverage
Table 3 Hazard ratios for new-onset diabetesa in patients receiving high-potency statins
Number of patients Number of cases Crude HR (95 % CI) Multiple adjustedb HR (95 % CI)
Low-potency statins 137 1 Reference Reference
High-potency statins 659 10 1.34 (0.17–10.50) 1.43 (0.18–11.74)
Abbreviations: HR hazard ratio, CI confidence interval
aDefined as diagnosis of diabetes or antidiabetic medication use
bAdjusted by age, sex, renal disease, and use of calcium-channel blockers
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[19]. After we had identified all of the patients who had
been prescribed lipid lowering drugs during the study
period, we selected the new users. Therefore, there may
be no difference between hospitals. Finally, the estimates
for the risk of new-onset diabetes with high-potency sta-
tins were underpowered. Further studies are needed to
examine the association between high-potency statins
and diabetes using larger cohorts.
Conclusions
The use of high-potency statins may increase HbA1c
levels in patients irrespective of the presence of diabetes;
however, the effect may be slightly more prominent in pa-
tients with diabetes. Treatment of hyperlipidemia with sta-
tins is important in the prevention of cardiovascular
disease. However, our findings suggest that glycemic con-
trol should be closely monitored throughout treatment.
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